Article Information
History
- February 15, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Gunar Günther, MD1,2,†,
- Lorenzo Guglielmetti, MD3,4,
- Claude Leu, MD1,
- Christoph Lange, MD5,6,7,8,
- Frank van Leth, PhD9,
- TBnet*
- 1Department of Pulmonary Medicine and Allergology, Inselspital, Bern University Hospital, University of Bern, Switzerland
- 2Department of Medical Sciences, School of Medicine, University of Namibia, Windhoek, Namibia
- 3Sorbonne Université, INSERM, U1135, Centre d’Immunologie et des Maladies Infectieuses, Cimi-Paris, équipe 2, Paris, France
- 4APHP, Groupe Hospitalier Universitaire Sorbonne Université, Hôpital Pitié-Salpêtrière, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux, Paris, France
- 5Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany
- 6German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany
- 7Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany
- 8Baylor College of Medicine and Texas Children’s Hospital, Global TB Program, Houston, TX, USA
- 9Department of Health Sciences, VU University, Amsterdam, The Netherlands; Amsterdam Public Health research institute, Amsterdam, The Netherlands
- ↵†Corresponding author: Gunar Günther MD, Department of Pulmonary Medicine and Allergology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 15, 3010 Bern, Switzerland, Email: gunar.guenther{at}insel.ch; phone: 0041 31 6321900
↵* Contributors of TBnet participating in this study are listed in the acknowledgements
Posted February 15, 2022.
Cost and availability of drugs and treatment regimens and availability of drug resistance testing for tuberculosis in Europe
